Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Sunitinib malate by Pfizer for Squamous Cell Carcinoma: Likelihood of Approval
Sunitinib malate is under clinical development by Pfizer and currently in Phase II for Squamous Cell Carcinoma. According to GlobalData,...
Sunitinib malate by Pfizer for Thymoma (Thymic Epithelial Tumor): Likelihood of Approval
Sunitinib malate is under clinical development by Pfizer and currently in Phase II for Thymoma (Thymic Epithelial Tumor). According to...
Sunitinib malate by Pfizer for Basaloid Squamous Cell Carcinoma: Likelihood of Approval
Sunitinib malate is under clinical development by Pfizer and currently in Phase II for Basaloid Squamous Cell Carcinoma. According to...